Major Depressive Disorder

Jun 23, 2026

Definium Therapeutics Advances DT120 ODT with Positive Results from Pivotal Phase 3 EMERGE Study Definium Therapeutics, Inc. reported positive topline findings from Emerge, its first Phase 3 randomized, double-blind, placebo-controlled trial assessing a single 100 µg dose of DT120 (lysergide) orally disintegrati...

Apr 23, 2025

One in every eight people worldwide lives with a psychiatric disorder—a staggering statistic that underscores the deep and growing impact of mental illness on global health. The mental health crisis has evolved into a pressing public health emergency, fueled by increasing social pressures, lifestyle changes, enviro...

Mar 13, 2025

Caristo Wins FDA Clearance for AI Solution to Prevent Heart Attacks Caristo Diagnostics, focused on transforming the diagnosis and treatment of cardiovascular disease, has announced that its CaRi-Plaque technology has received 510(k) clearance from the FDA. CaRi-Plaque is an AI-powered image analysis tool design...

Mar 05, 2025

Major Depressive Disorder (MDD) is a widespread and debilitating psychiatric condition that continues to challenge patients, caregivers, and healthcare systems worldwide. Characterized by persistent sadness, loss of interest, cognitive dysfunction, and suicidal ideation, MDD remains a major public health concern. D...

Mar 02, 2025

Fabre-Kramer Pharmaceuticals’ major depressive disorder drug, gepirone, faced FDA rejection not once, not twice, but three times since the beginning of the 21st century. Finally, the company can rejoice as the FDA has granted long-awaited approval. On 29 September 2023, the FDA approved Fabre-Kramer Pharmaceuticals...

Mar 02, 2025

In the contemporary world, major depressive disorder (MDD) is one of the diseases responsible for the greatest healthcare burden. In the United States, more than 24 million people suffer from major depressive disorder each year, while in Europe, about 20 million are diagnosed with the major depressive disorder each...

Feb 28, 2025

The Major Depressive Disorder drug treatment market is expanding rapidly due to the increasing demand for antidepressants and the disease’s profound impact on quality of life. In 2023, the major depressive disorder market across the 7MM was valued at an impressive USD 7.2 billion, and it’s poised for even greater e...

Feb 21, 2025

Johnson & Johnson’s SPRAVATO, which is already on track to become a blockbuster drug, has received a significant boost with the FDA’s approval for its use as a standalone treatment for major depressive disorder (MDD). Initially approved in 2019, SPRAVATO was authorized for use alongside an oral antidepressant i...

Aug 21, 2023

In a bittersweet decision for Biogen and Sage Therapeutics, the FDA approved the fast-acting drug zuranolone as the first tablet for postpartum depression on 04 August —but rejected the drug for major depressive disorder treatment. Zurzuvae is a neuroactive steroid that acts as a GABA-A receptor-positive allosteric...

Jul 20, 2023

Relievant Medsystems Launched New Tools for its Ablation System On June 14, 2023, Relievant Medsystems announced that it launched its next-generation access instruments for the Intracept procedure. Chronic vertebrogenic low back pain is treated with Intracept, a minimally invasive, same-day, outpatient proced...